iData Insights

Auris Medical Holding AG - Product Pipeline Review – 2015

Press Release   •   Dec 07, 2015 14:11 IST

Auris Medical Holding AG - Product Pipeline Review - 2015 Summary Global Markets Direct s, Auris Medical Holding AG - Product Pipeline Review - 2015, provides an overview of the Auris Medical Holding AGs pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Auris Medical Holding AGs, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Auris Medical Holding AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Auris Medical Holding AGs human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Auris Medical Holding AGs pipeline products Reasons to buy - Evaluate Auris Medical Holding AGs strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Auris Medical Holding AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Auris Medical Holding AGs R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Auris Medical Holding AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Auris Medical Holding AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Auris Medical Holding AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues

Browse Complete Report with TOC @

To Get Sample Copy of Report visit @

Table of Contents

Table of Contents

2 List of Tables

4 List of Figures

4 Auris Medical Holding AG Snapshot

5 Auris Medical Holding AG Overview

5 Key Information

5 Key Facts

5 Auris Medical Holding AG Research and Development Overview

6 Key Therapeutic Areas

6 Auris Medical Holding AG Pipeline Review

8 Pipeline Products by Stage of Development

8 Pipeline Products Monotherapy

9 Pipeline Products Partnered Products

10 Partnered Products/Combination Treatment Modalities

11 Auris Medical Holding AG Pipeline Products Glance

12 Auris Medical Holding AG Late Stage Pipeline Products

12 Phase III Products/Combination Treatment Modalities

12 Auris Medical Holding AG Clinical Stage Pipeline Products

13 Phase II Products/Combination Treatment Modalities

13 Auris Medical Holding AG Early Stage Pipeline Products

14 Preclinical Products/Combination Treatment Modalities

14 Auris Medical Holding AG Drug Profiles

15 esketamine hydrochloride

15 Product Description

15 Mechanism of Action

15 R&D Progress

15 XG-102 16 Product Description

16 Mechanism of Action

16 R&D Progress

16 AM-102

18 Product Description

18 Mechanism of Action

18 R&D Progress

18 AM-123

19 Product Description

19 Mechanism of Action

19 R&D Progress

19 Auris Medical Holding AG Pipeline Analysis

20 Auris Medical Holding AG Pipeline Products by Target

20 Auris Medical Holding AG Pipeline Products by Route of Administration

21 Auris Medical Holding AG Pipeline Products by Molecule Type

22 Auris Medical Holding AG Pipeline Products by Mechanism of Action

23 Auris Medical Holding AG Recent Pipeline Updates

24 Auris Medical Holding AG Locations And Subsidiaries

29 Head Office

29 Other Locations & Subsidiaries

29 Appendix 30 Methodology

30 Coverage

30 Secondary Research

30 Primary Research

30 Expert Panel Validation

30 Contact Us

30 Disclaimer 31

Read More @

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

Contact Us:
iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects.